Communications Biology (Mar 2023)
From a genome-wide screen of RNAi molecules against SARS-CoV-2 to a validated broad-spectrum and potent prophylaxis
- Ohad Yogev,
- Omer Weissbrod,
- Giorgia Battistoni,
- Dario Bressan,
- Adi Naamati,
- Ilaria Falciatori,
- Ahmet Can Berkyurek,
- Roni Rasnic,
- Rhys Izuagbe,
- Myra Hosmillo,
- Shaul Ilan,
- Iris Grossman,
- Lauren McCormick,
- Christopher Cole Honeycutt,
- Timothy Johnston,
- Matthew Gagne,
- Daniel C Douek,
- Ian Goodfellow,
- Gregory James Hannon,
- Yaniv Erlich
Affiliations
- Ohad Yogev
- Eleven Therapeutics
- Omer Weissbrod
- Eleven Therapeutics
- Giorgia Battistoni
- Eleven Therapeutics
- Dario Bressan
- Eleven Therapeutics
- Adi Naamati
- Eleven Therapeutics
- Ilaria Falciatori
- Eleven Therapeutics
- Ahmet Can Berkyurek
- Eleven Therapeutics
- Roni Rasnic
- Eleven Therapeutics
- Rhys Izuagbe
- University of Cambridge, Department of Pathology, Division of Virology
- Myra Hosmillo
- University of Cambridge, Department of Pathology, Division of Virology
- Shaul Ilan
- Eleven Therapeutics
- Iris Grossman
- Eleven Therapeutics
- Lauren McCormick
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Christopher Cole Honeycutt
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Timothy Johnston
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Matthew Gagne
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Daniel C Douek
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Ian Goodfellow
- University of Cambridge, Department of Pathology, Division of Virology
- Gregory James Hannon
- CRUK Cambridge Institute, University of Cambridge, Li Ka Shing Centre
- Yaniv Erlich
- Eleven Therapeutics
- DOI
- https://doi.org/10.1038/s42003-023-04589-5
- Journal volume & issue
-
Vol. 6,
no. 1
pp. 1 – 12
Abstract
A genome-wide screen of 16,471 RNAi triggers targeting SARS-CoV-2 genome by Sens.AI. identifies hyper-potent RNAi candidates against SARS-CoV-2 that are further validated in vitro and in vivo.
